Methylation status of Vitamin D receptor gene promoter in benign and malignant adrenal tumors

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Pilon, Catia ^a   Rebellato, Andrea ^a   Urbanet, Riccardo ^a   Guzzardo, Vincenza ^a   Cappellesso, Rocco ^a   Sasano, Hironobu ^b   Fassina, Ambrogio ^a   Fallo, Francesco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; DNA; MESSENGER RNA; PYRIMIDINE NUCLEOTIDE; VITAMIN D RECEPTOR;

ADRENAL CANCER; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; HYPERCORTISOLISM; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; VDR GENE;

EID: 84957067473     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/375349     Document Type: Article

References (30)

1. C. J. Rosen, J. S. Adams, D. D. Bikle, et al., "The nonskeletal effects of vitamin D: an endocrine society scientific statement, " Endocrine Reviews, vol. 33, no. 3, pp. 456-492, 2012.
2. C. Carlberg, S. Seuter, and S. Heikkinen, "The first genomewide viewof vitaminDreceptor locations and their mechanistic implications, " Anticancer Research, vol. 32, no. 1, pp. 271-282, 2012.
3. J. W. Pike, M. B. Meyer, and K. A. Bishop, "Regulation of target gene expression by the vitamin D receptor-an update onmechanisms, " Reviews in Endocrine andMetabolic Disorders, vol. 13, no. 1, pp. 45-55, 2012.
4. I. S. Fetahu, J. Hobaus, and E. Kallay, "Vitamin D and the epigenome, " Frontiers in Physiology, vol. 5, article 164, 2014.
5. C. Leyssens, L. Verlinden, and A. Verstuy, "Antineoplastic effects of 1, 25(OH)2D3 and its analogs in breast, prostate and colorectal cancer, " Endocrine-Related Cancer, vol. 20, no. 2, pp. R31-R47, 2013.
6. L. Vuolo, C. Di Somma, A. Faggiano, and A. Colao, "VitaminD and cancer, " Frontiers in Endocrinology, vol. 3, article 58, 2012.
7. D. D. Bikle, "Vitamin D and cancer: the promise not yet fulfilled, " Endocrine, vol. 46, no. 1, pp. 29-38, 2014.
8. G. Muscogiuri, B. Altieri, M. Penna-Martinez, and K. Badenhoop, "Focus on vitamin D and the adrenal gland, " Hormone and Metabolic Research, vol. 47, no. 4, pp. 239-246, 2015.
9. L. Yang, J. Ma, X. Zhang, Y. Fan, and L. Wang, "Protective role of the vitamin D receptor, " Cellular Immunology, vol. 279, no. 2, pp. 160-166, 2012.
10. C. Pilon, R. Urbanet, T. A. Williams, et al., "1, 25-Dihydroxyvitamin D(3) inhibits the human H295R cell proliferation by cell cycle arrest: a model for a protective role of vitamin D receptor against adrenocortical cancer, " Journal of Steroid Biochemistry and Molecular Biology, vol. 140, pp. 26-33, 2014.
11. A. M. Lerario, A. Moraitis, and G. D. Hammer, "Genetics and epigenetics of adrenocortical tumors, " Molecular and Cellular Endocrinology, vol. 386, no. 1-2, pp. 67-84, 2014.
12. N. S. Rechache, Y. Wang, H. S. Stevenson, et al., "DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors, " Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. E1004-E1013, 2012.
13. A. L. Fonseca, J. Kugelberg, L. F. Starker, et al., "Comprehensive DNAmethylation analysis of benign andmalignant adrenocortical tumors, " Genes Chromosomes and Cancer, vol. 51, no. 10, pp. 949-960, 2012.
14. O. Barreau, G. Assié, H. Wilmot-Roussel, et al., "Identification of a CpG island methylator phenotype in adrenocortical carcinomas, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 1, pp. E174-E184, 2013.
15. B. Howard, Y. Wang, P. Xekouki, et al., "Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas, " Journal of Clinical Endocrinology andMetabolism, vol. 99, no. 3, pp. E536-E543, 2014.
16. L. M. Weiss, L. J. Medeiros, and A. L. Vickery Jr., "Pathologic features of prognostic significance in adrenocortical carcinoma, " American Journal of Surgical Pathology, vol. 13, no. 3, pp. 202-206, 1989.
17. S. Aubert, A. Wacrenier, X. Leroy, et al., "Weiss systemrevisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors, " American Journal of Surgical Pathology, vol. 26, no. 12, pp. 1612-1619, 2002.
18. M. Fassnacht, S. Johanssen, M. Quinkler, et al., "Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM Classification, " Cancer, vol. 115, no. 2, pp. 243-250, 2009.
19. C. W. Miller, R. Morosetti, M. J. Campbell, S. Mendoza, and H. P. Koeffler, "Integrity of the 1, 25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers, "Molecular Carcinogenesis, vol. 19, no. 4, pp. 254-257, 1997.
20. G. Assié, E. Letouzé, M. Fassnacht, et al., "Integrated genomic characterization of adrenocortical carcinoma, " Nature Genetics, vol. 46, no. 6, pp. 607-612, 2014.
21. R. Marik, M. Fackler, E. Gabrielson, et al., "DNA methylationrelated vitaminDreceptor insensitivity in breast cancer, " Cancer Biology &Therapy, vol. 10, no. 1, pp. 44-53, 2010.
22. K.-I. Miyamoto, R. A. Kesterson, H. Yamamoto, et al., "Structural organization of the human vitamin D receptor chromosomal gene and its promoter, "Molecular Endocrinology, vol. 11, no. 8, pp. 1165-1179, 1997.
23. M. Rodríguez-Paredes and M. Esteller, "Cancer epigenetics reaches mainstream oncology, " Nature Medicine, vol. 17, no. 7, pp. 330-339, 2011.
24. S. A. Abedin, C. M. Banwell, K. W. Colston, C. Carlberg, and M. J. Campbell, "Epigenetic corruption of VDR signalling in malignancy, " Anticancer Research, vol. 26, no. 4, pp. 2557-2566, 2006.
25. R. Sirianni, F. Zolea, A. Chimento, et al., "Targeting estrogen receptor-reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: Potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment, " Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. E2238-E2250, 2012.
26. T. Mohri, M. Nakajima, S. Takagi, S. Komagata, and T. Yokoi, "MicroRNA regulates human vitaminDreceptor, " International Journal of Cancer, vol. 125, no. 6, pp. 1328-1333, 2009.
27. P. Singh, P. S. H. Soon, J.-J. Feige, et al., "Dysregulation of microRNAs in adrenocortical tumors, " Molecular and Cellular Endocrinology, vol. 351, no. 1, pp. 118-128, 2012.
28. T. Else, A. C. Kim, A. Sabolch, et al., "Adrenocortical carcinoma, " Endocrine Reviews, vol. 35, no. 2, pp. 282-326, 2014.
29. Y. Xu, Y. Qi, Y. Zhu, G. Ning, and Y. Huang, "Molecular markers and targeted therapies for adrenocortical carcinoma, " Clinical Endocrinology, vol. 80, no. 2, pp. 159-168, 2014.
30. T. Wang and W. E. Rainey, "Human adrenocortical carcinoma cell lines, " Molecular and Cellular Endocrinology, vol. 351, no. 1, pp. 58-65, 2012.